HeartBeat.bio Joins Forces with Boehringer Ingelheim to Advance Gene Therapies for Inherited Heart Muscle Disorders

07-Oct-2025 - HeartBeat.bio has entered into a research collaboration with Boehringer Ingelheim to develop gene therapy-based treatments for genetic cardiomyopathies. The partnership combines Boehringer Ingelheim’s expertise in gene therapy drug development with HeartBeat.bio’s proprietary Cardioid Drug ...

Topas Therapeutics and Boehringer Ingelheim sign multi-year collaboration

Initial focus on next generation vector-based therapeutics

26-Apr-2018 - Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform company leveraging the natural tolerance induction capabilities of the liver, today announced that it has signed a multi-year agreement with Boehringer Ingelheim to collaborate in the field of antigen-specific tolerance ...

Ablynx receives EUR 5 million in milestone payment from Alzheimer's disease collaboration with Boehringer Ingelheim

28-Jun-2011 - Ablynx announced that it has earned a €5 million milestone payment following Boehringer Ingelheim's decision to initiate development with the lead Nanobody candidate that was selected in May 2010. In January 2007, Boehringer Ingelheim and Ablynx announced a worldwide research and licensing ...

Evotec Receives Twelfth Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim

10-May-2011 - Evotec AG announced that its research alliance with Boehringer Ingelheim has achieved a twelfth milestone triggering a payment of EUR 2.0 million to Evotec. The milestone reached was on the transition of an oncology programme into lead optimisation.Dr Mario Polywka, Chief Operating Officer of ...

Nanobody lead candidate selected by Boehringer Ingelheim for development in Alzheimer's Disease

25-May-2010 - Ablynx announced that Boehringer Ingelheim has selected a Nanobody lead candidate for further development for the treatment of Alzheimer's disease. This is the first lead candidate emerging from the Alzheimer's disease collaboration between Ablynx and Boehringer Ingelheim, and will result in a ...

Evotec and Boehringer Ingelheim Extend and Broaden Research Collaboration

Strategic research collaboration continues for another 4 years at a value of EUR 15 million plus milestones and royalties

10-Nov-2009 - Evotec AG announced that it has extended the research collaboration with Boehringer Ingelheim for a further 4 years. The collaboration was initiated in August 2004 and has been extended on two previous occasions. At the same time, based on the success to date in the areas of CNS, inflammation, ...

Evotec Receives a EUR 2.5 Million Milestone Payment in its Research Collaboration with Boehringer Ingelheim

23-Oct-2009 - Evotec AG announced that it has achieved another milestone in its research collaboration with Boehringer Ingelheim. The collaboration, which was initiated in August 2004, has up to now resulted in seven milestone payments. The achievement of the current milestone has led to a payment to Evotec ...

Orexo and Boehringer Ingelheim Extend Their Research Collaboration

10-Sep-2008 - Orexo AB and Boehringer Ingelheim have extended their existing three year research collaboration for a further 12 months from November 2008. The research collaboration is a part of an exclusive world-wide license to develop and market a new class of drugs with a novel mechanism of action for the ...

Graffinity and Boehringer Ingelheim Pharmaceuticals enter into drug discovery research agreement

11-Sep-2006 - Graffinity Pharmaceuticals GmbH announced that it has entered into a research collaboration with Boehringer Ingelheim Pharmaceuticals, Inc. which involves four global research sites of Boehringer Ingelheim. Under the terms of the agreement, Graffinity will receive technology access fees and ...

Boehringer Ingelheim and NascaCell announce research collaboration on aptamers

18-Feb-2005 - Boehringer Ingelheim and NascaCell announced that they have entered into a research collaboration on aptamer based target validation and drug discovery. Under the agreement, NascaCell will provide Boehringer with custom aptamers for therapeutic targets. "We are delighted to work together with ...